흑폐병 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the black lung disease market is expected to grow from USD 2.64 billion in 2025 to USD 2.75 billion in 2026 and is forecasted to reach USD 3.53 billion by 2031 at 5.11% CAGR over 2026-2031.

Global Black Lung Disease Market Trends and Insights

Rising Coal Dust Exposure in Mining Operations

The black lung disease market continues to be driven by the changing composition of coal mine dust rather than by coal tonnage alone. Operators working thinner seams are exposing miners to higher respirable crystalline silica concentrations, and that exposure pattern is linked with faster disease progression and greater rates of progressive massive fibrosis in hard-hit coal regions. A 2025 CDC report showed that mortality remained heavily concentrated in Kentucky, West Virginia, Virginia, and Pennsylvania, and underground mining machine operators carried a sharply elevated proportionate mortality ratio relative to other extraction workers. For the black lung disease market, that means each diagnosed patient increasingly represents a higher-acuity care profile with more imaging, closer pulmonary follow-up, and greater dependence on supportive treatment pathways.

Expanded Occupational Health Screening Programs

The black lung disease market gains support when health surveillance programs expand because screening is the point where latent illness becomes billable, diagnostic, and treatment demand. Periodic chest imaging, spirometry, and reporting obligations under established surveillance frameworks create recurring demand that does not depend solely on acute hospital visits or severe disease presentation. This matters because a wider screening net identifies more early-stage cases, and those patients typically enter a longer sequence of follow-up testing, medication use, counseling, and rehabilitation over time. In the black lung disease market, broader surveillance also shifts care from reactive management toward structured monitoring, which improves visibility for laboratories, occupational clinics, and imaging providers. The link between institutional surveillance and recurring diagnostic utilization is reinforced by the continuing role of the Coal Workers' Health Surveillance Program in routine screening workflows.

Limited Disease-Specific Therapeutic Options

The black lung disease market remains constrained because there is still no approved curative or disease-modifying therapy labeled specifically for coal workers' pneumoconiosis. Current care depends on bronchodilators, corticosteroids, oxygen support, and antifibrotic agents that were developed for other fibrotic or interstitial lung conditions rather than for this disease itself. That weakens reimbursement certainty, narrows pharmaceutical differentiation, and keeps much of the black lung disease market centered on diagnostics and supportive care instead of branded therapy expansion. It also makes the revenue profile of this market very different from adjacent respiratory categories, where richer drug pipelines support stronger pricing and clearer treatment protocols. The same gap still leaves a meaningful opening for the first company that secures a labeled indication in coal workers' pneumoconiosis or progressive massive fibrosis, especially after progressive fibrosis approvals have shown that regulators will recognize adjacent fibrotic pathways.

Other drivers and restraints analyzed in the detailed report include:

1. AI-Enabled Radiology Improves Early Case Detection
2. Reimbursement Pressure Favors Earlier Diagnosis and Monitoring
3. High Cost of Advanced Care and Long-Term Oxygen Support

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Complicated coal workers' pneumoconiosis captured 44.31% of the black lung disease market share in 2025, which reflects the higher care intensity, heavier imaging needs, and broader treatment burden seen once patients reach advanced fibrotic disease. Within the black lung disease market, progressive massive fibrosis carries strategic importance beyond its case volume because it is associated with severe functional loss, higher mortality, and the greatest per-patient demand for specialist respiratory management. The revenue weight of advanced disease also shows why late-stage presentation still matters commercially, even as prevention and earlier surveillance continue to improve in selected regions.

Simple coal workers' pneumoconiosis is projected to expand at 5.54% CAGR through 2031, making it the fastest-growing disease category in the black lung disease market. That growth is being supported by broader screening coverage and by AI-assisted image review that can surface cases before clear functional deterioration is visible in routine workflows. In practical terms, rising simple CWP diagnoses in the black lung disease market often signal better case discovery rather than a straightforward increase in severe clinical burden within mature surveillance systems.

Complete Report Scope:

• By Disease Type
  • Simple Coal Workers' Pneumoconiosis
  • Complicated Coal Workers' Pneumoconiosis
  • Progressive Massive Fibrosis
• By Component
  • Diagnostic Method
    • Chest X-Ray
    • CT Scan
    • Pulmonary Function Test
    • Other Diagnostic Methods
  • Treatment Type
    • Medication
    • Oxygen Therapy
    • Pulmonary Rehabilitation
    • Lung Transplant
    • Stem Cell Therapy
    • Other Treatment Types
• By End-User
  • Hospitals
  • Specialty Clinics
  • Diagnostic Laboratories
  • Other End-Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America represented 47.16% of the black lung disease market in 2025, which made it the largest regional revenue center in the current period. The region benefits from a mature mix of compensation programs, surveillance obligations, specialist provider networks, and home respiratory care infrastructure that supports recurring treatment demand. Mexico still presents latent demand because informal mining activity in Coahuila remains less visible in formal occupational health systems, which means diagnosed care demand can rise later as access and documentation improve.

Europe is a more mature part of the black lung disease market, and demand there is weighted more toward long-term management of existing patients than toward rapid growth in new diagnoses. Western European countries benefit from sustained occupational safety enforcement, which has reduced fresh case intensity and shifted the care mix toward older survivors who need monitoring, symptom control, and fibrosis management rather than large screening expansion. In July 2026, the UK MHRA approved nerandomilast for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, which supports the region's role in premium respiratory therapy adoption and may have relevance for advanced coal-related fibrotic disease over time. Eastern Europe, especially Poland, remains a mid-tier opportunity where coal activity, legacy disease burden, and compliance investment can still support measured expansion within the black lung disease market.

Asia-Pacific is forecasted to grow at 7.27% CAGR through 2031, which makes it the fastest-expanding regional block in the black lung disease market. The region's growth reflects the continuing role of coal in energy security across China, India, and South Korea, and the persistence of screening and dust-control gaps in several mining systems. Australia shows a different profile because stronger regulatory enforcement supports earlier detection and more consistent treatment uptake per diagnosed case. Middle East and Africa and South America remain emerging opportunities where mining activity is growing faster than occupational health investment, leaving meaningful latent demand that could surface more clearly as surveillance depth improves.

1. Abbvie
2. AstraZeneca
3. Boehringer Ingelheim
4. Chiesi Farmaceutici
5. Cipla
6. Dr. Reddy's Laboratories
7. Roche
8. GE HealthCare Technologies Inc.
9. GlaxoSmithKline
10. Inogen
11. Merck
12. Novartis
13. Pfizer
14. Koninklijke Philips
15. Resmed
16. Sanofi
17. Siemens Healthineers
18. Sun Pharmaceuticals Industries
19. Teva Pharmaceutical Industries
20. Veracyte, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Coal Dust Exposure in Mining Operations
  • 4.2.2 Expanded Occupational Health Screening Programs
  • 4.2.3 AI-Enabled Radiology Improves Early Case Detection
  • 4.2.4 Reimbursement Pressure Favors Earlier Diagnosis and Monitoring
  • 4.2.5 Long-Term Survivor Management Increases Chronic Care Demand
  • 4.2.6 Underdiagnosis in Informal Mining Networks Drives Latent Demand
• 4.3 Market Restraints
  • 4.3.1 Limited Disease-Specific Therapeutic Options
  • 4.3.2 High Cost of Advanced Care and Long-Term Oxygen Support
  • 4.3.3 Uneven Access to Occupational Lung Screening in Emerging Markets
  • 4.3.4 Medico-Legal Underreporting Slows Case Recognition and Treatment Uptake
• 4.4 Supply/Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Disease Type
  • 5.1.1 Simple Coal Workers' Pneumoconiosis
  • 5.1.2 Complicated Coal Workers' Pneumoconiosis
  • 5.1.3 Progressive Massive Fibrosis
• 5.2 By Component
  • 5.2.1 Diagnostic Method
    • 5.2.1.1 Chest X-Ray
    • 5.2.1.2 CT Scan
    • 5.2.1.3 Pulmonary Function Test
    • 5.2.1.4 Other Diagnostic Methods
  • 5.2.2 Treatment Type
    • 5.2.2.1 Medication
    • 5.2.2.2 Oxygen Therapy
    • 5.2.2.3 Pulmonary Rehabilitation
    • 5.2.2.4 Lung Transplant
    • 5.2.2.5 Stem Cell Therapy
    • 5.2.2.6 Other Treatment Types
• 5.3 By End-User
  • 5.3.1 Hospitals
  • 5.3.2 Specialty Clinics
  • 5.3.3 Diagnostic Laboratories
  • 5.3.4 Other End-Users
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 AbbVie Inc.
  • 6.3.2 AstraZeneca plc
  • 6.3.3 Boehringer Ingelheim International GmbH
  • 6.3.4 Chiesi Farmaceutici S.p.A.
  • 6.3.5 Cipla Limited
  • 6.3.6 Dr. Reddy's Laboratories Ltd.
  • 6.3.7 F. Hoffmann-La Roche Ltd
  • 6.3.8 GE HealthCare Technologies Inc.
  • 6.3.9 GlaxoSmithKline plc
  • 6.3.10 Inogen, Inc.
  • 6.3.11 Merck & Co., Inc.
  • 6.3.12 Novartis AG
  • 6.3.13 Pfizer Inc.
  • 6.3.14 Philips Healthcare
  • 6.3.15 ResMed Inc.
  • 6.3.16 Sanofi S.A.
  • 6.3.17 Siemens Healthineers AG
  • 6.3.18 Sun Pharmaceutical Industries Ltd.
  • 6.3.19 Teva Pharmaceutical Industries Ltd.
  • 6.3.20 Veracyte, Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment